

# REMARKS

Upon entry of the foregoing amendment, Claims 1-54 are canceled, and Claims 55-95 are pending in the application. No new matter has been introduced. Allowance of all pending claims in view of the following remarks is respectfully requested.

**The currently submitted claims are supported by the specification as set forth below:**

Claim	Feature	Paragraph
55	A method for selective cytolysis of a target cell, comprising: contacting said target cell with an adenovirus vector comprising a cell type-specific transcriptional regulatory element (TRE) operably linked to a first adenovirus gene essential for replication selected from the group consisting of E1A, E1B and E4, wherein when said adenovirus vector enters said target cell, expression of said adenovirus gene under control of said cell type-specific TRE occurs and selective cytolysis of said target cell results.	Selective cytolysis (page 21, line 24 to page 22, line 2); target cell (page 16, lines 20-22); adenovirus vector comprising a cell type-specific transcriptional regulatory element (TRE) operably linked to a first adenovirus gene essential for replication (page 5, lines 14-20); E1A, E1B and E4 (page 28, lines 7-11); selective cytolysis of said target cell results (page 9, lines 25-28).
56, 76	target cell is a cancer cell	Page 10, lines 11-12
57, 77	cell type-specific transcriptional response elements (TREs)	Page 11, lines 1-5
58, 78	adenovirus vector further comprises a transgene	Page 9, lines 19-23
59, 79	transgene is a cytotoxic gene.	Page 22, lines 7-9
60, 80	cytotoxic gene is HSV-thymidine kinase (HSV-tk) or cytosine deaminase (cd)	Page 40, lines 17-23
61-62; 81-82	transgene is a cytokine gene such as GM-CSF	Page 41, lines 4-6
63-64; 83-85	adenovirus vector further comprises the coding sequence for ADP	Page 41, line 20 – page 42, line 5
65, 85	ADP is inserted in the E3 region	page 42, lines 9-12
66-69; 86-89	cell type-specific TRE is a prostate specific TRE selected from the group consisting of a PSA-TRE, a PB-TRE and an hKLK2-TRE	Page 29, lines 6-14
70-72, 90-92	PSA-TRE comprises a prostate specific antigen enhancer (comprises nucleotides -5322 and -3739 relative to the transcription start site of prostate specific antigen gene) and promoter (comprises nucleotides -540 to +8 relative to transcription start site of prostate specific antigen gene)	Page 29, lines 15-20

Claim	Feature	Paragraph
73	adenovirus vector further comprises a second cell type-specific TRE	Page 5, line 27 – page 6, line 1
74	first and second cell type-specific TREs are substantially identical	Page 26, lines 15-20
75	first and second cell type-specific TREs are different	Page 37, lines 17-24

#### CONCLUSION


Applicants submit that all of the claims are now in condition for allowance, which action is requested. If the Examiner finds that a Telephone Conference would expedite the prosecution of this application, she is invited to telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any other fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number CELL-004CON.

Respectfully submitted,

Date: Oct. 6, 2004

By:



Pamela J. Sherwood, Ph.D.  
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, CA 94303  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231